Nilaya Varma, Co-Founder and Group CEO, Primus Partners, shared his view that these approvals are significant as they mark a shift towards outcome-based, precision-medicine approaches in routine cancer care. He noted that combination immunotherapies, in particular, are expected to improve outcomes for patient segments that previously had limited therapeutic options.